Etonogestrel
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
| |
| Etonogestrel
| |
| Systematic (IUPAC) name | |
| 13-ethyl-17-ethynyl- 17-hydroxy-11-methylidene- 2,6,7,8,9,10,12,13,14,15,16,17- dodecahydro- 1H-cyclopenta[a] phenanthren-3-one | |
| Identifiers | |
| CAS number | |
| ATC code | G03 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C22H28O2 |
| Mol. mass | 324.457 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | Hepatic (P450 3A4) |
| Half life | 25 hours |
| Excretion | Urinary (majority) and fecal |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status |
Prescription Only (S4)(AU) POM(UK) ℞-only(US) ℞ Prescription only |
| Routes | Subdermal as slow-release implant |
|
WikiDoc Resources for Etonogestrel | |
|
Articles | |
|---|---|
|
Most recent articles on Etonogestrel Most cited articles on Etonogestrel | |
|
Media | |
|
Powerpoint slides on Etonogestrel | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Etonogestrel at Clinical Trials.gov Clinical Trials on Etonogestrel at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Etonogestrel
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Etonogestrel Discussion groups on Etonogestrel Patient Handouts on Etonogestrel Directions to Hospitals Treating Etonogestrel Risk calculators and risk factors for Etonogestrel
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Etonogestrel | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Businness | |
|
Experimental / Informatics | |
Etonogestrel is a molecule used in hormonal contraceptives, most notably the subdermal implant Implanon.
Etonogestrel, the specific progestin used in NuvaRing, is the active metabolite of the inactive prodrug desogestrel, one of two third-generation progestins found in some epidemiological studies of combined oral contraceptive pills to be associated with a higher risk of venous thrombosis than combined oral contraceptive pills containing certain second-generation progestins. Because hormones are released continuously from NuvaRing, peak and total estrogen and progestin doses are significantly lower than with combined oral contraceptives, although it is not known whether this lowers the risk of blood clots.
See also
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
